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GUR-
Efficacy of centpropazine, a new antidepressant, hasbeen evaluated in fortytwo patientsof'endogenous 
depression. The 4 week open trial was carried out in a dose-range of 40 to 120mgper day. A significant 
lowering of Hamilton Depression Rating Scale (HDRS) score was observed in 34 patient. The 
antidepressant effect could be detected in 9 patients within one week, in 28 cases in two weeks and in 
all the 34 patients by third week. Giddiness, headache, dryness of mouth and weakness were reported 
by 11 patients. ^^^^^^ 
Centpropazine [1-propionyl-phenoxy)-
3-(r<r-phenyl-piperazinyl)propane-2-01] is a 
new antidepressant with minimal autonomic ef-
fects in animals (Prasad et al., 1969). This com-
pound counteracts reserpine induced 
hypothermia, ptosis and sedation and poten-
tiates amphetamine induced hyperactivity in 
mice. Centpropazine does not antagonize the 
pilocarpine induced salivation and its an-
titremorine activity is weaker than that of im-
ipramine. The receptor binding studies have 
shown that centpropazine decreases S-HT 
receptor density in cortical region (Hussain et 
al., 1988). The study on noradrenergic recep-
tors has shown it to have a greater affinity with 
alpha receptors and modulatory effect on 
second messanger system (Dikshit et al., 1992). 
It has been found to be safe in chronic 
toxicological evaluation including 
teratogenicity and mutagenicity studies (un-
published data). Phase I clinical trial with this 
potential drug were undertaken succesfully in 
normal male subjects and was found to be safe 
upto a dose of 200mg in single dose studies and 
upto 80mg per day in multiple dose studies 
(Gupta et al., 1989). The aim of phase II clinical 
trial was to evaluate centpropazine for an-
tidepressant effect and nature of side effectes in 
patients suffering from depression. 
METHODS 
The trial was conducted at the following 
centres in collaboration with. Central Drug Re-
search Institute,Xucknow. 
Deptt, of Seth G.S. Medical College, 
Psychiatry Bombay. 
„ Ram Manohar Lohia Hospital, 
New Delhi. 
„ K,G.'s Medical College, 
Lucknow. 
„ Govt. Medical College, Patiala. 
Patients of either sex suffering from 
major depressive disorder (endogenous 
depression) were recruited for the study. The 
diagnosis was made in accordance with Re-
search Diagnostic Criteria (Spitzer et al., 1978). 
All patients were admitted in the hospital and 
were subjected to a thorough clinical examina-
tion and biochemical laboratory investigations 
to rule out any hepatic, renal, cardiac or organic 
brain disease. An informed consent was ob-
tained from the patients or his/her guardians. 
The initial dose was 40 mg per day and it was 
increased upto 120 mg in two weeks and con-
tinued on this dose upto 4 weeks. Patients 
receiving any other psychotropic drugs before 
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entering the trial underwent 2 weeks placebo 
washout period before inclusion. Each patient 
was evaluated on Hamilton Depression Rating 
Scale (HDRS) and Side Effect Symptom Check 
List (SESCL) on day 0, 7,14, 21 and 28 of the 
trial. The criterian for onset of antidepressant 
effect was 25 percent reduction in HDRS score 
of the individual patient. Clinical global impres-
sion scale was used for final mental status 
evaluation at the end of the trial. The clinical 
examination and laboratory investigations were 
repeated at the end of the trial. The data has 
been presented as mean ±SD and analysed by 
paired't' test for statistical significance. 
RESULTS 
In the present study 42 patients (30 
males and 12 females) with mean age of 
38.6± 11.0 years suffering from depression com-
* pleted the 4 week trial. The results have been 
presented for each centre separately. 
BOMBAY CENTRE 
Eleven patients (8 males and 3 females) 
aged 28 to 54 years (mean 41.3±8.4) were in-
cluded in the trial. One patient was withdrawn 
from the study because of increased severity of 
illness and one patient dropped due to his in-
ability to come for follow up visit. The mean 
HDRS score at intervals show a steady and 
statistically significant decrease (Table 1). 
After one week of therapy with centpropazine 
onset of effect was observed in 3 cases, 3 cases 
showed improvemnt at 2 weeks and 2 cases had* 
signs of improvemnt after 3 weeks. At the end 
of 4 week therapy final evaluation on Clinical 
Global Impression Scale (CGIS) revealed that 
two patients were very much improved, 6 
patients showed mild to moderate improvemnt 
and 1 case had no improvemnt. 
DELHI CENTRE 
Seven patients (4 male and 3 female) 
aged 22 to 65 years (mean 43.33 ±16.48) were 
included in the trial. One patient was lost to 
follow up. However, 6 patients completed the 
study. The fall in mean HDRS scores at weekly 
intervals was found to be statistically significant 
in these patients (Table). Onset of antidepres-
sive effect was noticed in 2 pateints at 1 week, 3 
patient at 2 week and in 1 pateint at 3 weeks of 
centpropazine therapy. The evaluation on 
CGIS at the end of trial showed that 2 patients 
were very much improved and 4 pateints ex-
perienced mild to moderate improvemnt. 
LUCKNOW CENTRE 
The study was initiated on 24 patients (16 
male and 8 female) aged 24 to 57 years (mean 
42.81±9.5 years). Five patients dropped during 
their follow up visits. However, 19 patients com-
pleted the study. A statistically significant 
decrease in mean HDRS scores was observed 
after 2 weeks of drug therapy (Table). Three 
pateints started improving as early as 1 week, 8 
patients showed improvemnt at 2 week and 1 
patient experienced improvemnt at 3 weeks. 
The final evaluation on CGIS revealed a mild to 
moderate improvement in 12 patients whereas 
no change was observed in 7 patients. 
PATIALA CENTRE 
Ten patients (7 male, 3 female) aged 28 
to 55 years (mean 38.8+14 years) were in-
cluded. Two patients were dropped as they 
could not come for follow up. Eight patients 
completed the trial. The mean HDRS scores at 
weekly intervals have shown a steady fall which 
was found to be statistically significant (Table). 
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patient at 1 week, 5 started improving at 2 week 
and 2 showed improvement at 3 weeks. The final 
clinical evaluation on CGIS revealed that 4 
patients were very much improved. 3 patients 
showed mild to moderate improvemet and 1 
case showed no change. 
The final clinical assessment at the endof 
the trial from the 4 centres revealed that 8 
patients were very much improved, 26 patients 
showed a mild to moderate improvemet while 8 
patients remained unchanged. The analysis of 
side effects (SESCL) has shown that eleven 
patients complained of giddiness, headache, 
dryness of mouth and weakness. These were 
transient and did not interfere in day to day 
routine of the patient or the treatment schedule. 
No drug effect were observed on clinical ex-
amintion and laboratory parameters. 
Table 1: Showing pre- and post-drug HDRS scores (Values expressed as mean ±SD) 
Centre 
Bombay (n=9) 
Delhi (n=6) 
Lucknow (n = 19) 
Patiala(n=8) 
DayO 
32.11 
±6.17 
39.66 
±5.35 
31.52 
±6.71 
35.37 
±8.39 
±lwk 
24.11** 
±4.19 
31.83* 
±10.06 
28.63 
±6.85 
28.25** 
±738 
±2wk 
1933** 
±7.36 
23* 
±11.29 
24.73** 
±7.63 
17.5** 
±731 
±3wk 
15.11** 
±7.52 
19.83* 
±15.72 
22.31** 
±8.41 
1137*** 
±7.63 
±4wk 
12.66** 
±7.01 
12.83* 
±11.32 
18.63** 
±7.68 
7.12** 
±4.22 
(*p < 0.05, **p< 0.01) 
DISCUSSION 
The present communication reports the 
findings of multicentric clinical trials carried 
out with centpropazine in patients of depres-
sion at four centres in India in collaboration 
with Central Drug Research Institute, Luck-
now. 
The study has shown antidepressant 
response in 80.9% patients at the end of 4 weeks 
medication with centpropazine*. The an-
tidepressant effect was present in 9 patients 
after one week, in 28 patient after 2 weeks and 
in 34 patients after 3 weeks of therapy. 
Centpropazine has also shown a wider safety 
margin in acute toxicity studies as compared to 
imipramine and could be safer than tricylics in 
overdosage by suicidal patients, a persistent risk 
in severely depressed pateints. The side effects 
were also mild and were transient. 
The preliminary studies have, therefore, 
revealed that centpropazine has antidepressant 
effect with safer profile in a small population of 
42 patients. The drug is currently undergoing a 
double blind phase III clinical trial. 
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